Romiplostim versus Placebo for Chemotherapy-Induced Thrombocytopenia
2 institutional releases
Published in New England Journal of Medicine · View the paper (DOI)
A phase 3 clinical trial by Mass General Brigham reveals romiplostim's ability to prevent chemotherapy-induced thrombocytopenia, allowing full-dose chemotherapy delivery. The medication boosts bone marrow's resistance to chemotherapy, reducing the risk of life-threatening bleeding and improving cancer treatment outcomes.
Coverage from 2 institutions
- Romiplostim prevents serious side effect of chemotherapy in phase 3 trial Mass General Brigham · Mar 12, 2026 · first to report
- Phase 3 study: New therapy keeps gastrointestinal cancer care on course when low platelets are an obstacle University of Miami Miller School of Medicine · Mar 16, 2026